Oren Zusman1, Guy Amit, Harel Gilutz, Doron Zahger. 1. Department of Cardiology, Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel. zusmanor@bgu.ac.il
Abstract
BACKGROUND: Atrial fibrillation (AF) in the setting of acute myocardial infarction (AMI) independently predicts in-hospital and long-term morbidity and mortality. Very little data exist regarding the prognostic significance and management of new-onset AF in this setting in the era of dual anti-platelet therapy. METHODS: We identified all patients admitted to our coronary care unit for AMI between 2002 and 2009 who developed new-onset AF. The control group was an age and gender matched group of AMI patients who did not have AF. Management and recurrent AF, non-fatal stroke, and mortality data were collected from subsequent hospitalizations and outpatient records. RESULTS: Of 1,991 AMI admissions, new-onset AF was diagnosed in 100 (4.1%). Patients' age was 70 (±12), 32% were female, 58% had ST-elevation AMI and 53% had moderate or worse systolic dysfunction. AF recurred during index admission in 33%. During mean follow-up of 41 months, AF recurred in 22 and 4.5%, and non-fatal stroke occurred in 13 and 1% of the AF and control groups, respectively (p < 0.01 for both). The composite of death and non-fatal stroke was also significantly higher in the AF group, 39 versus 29% (p = 0.02). Oral anti-coagulation was used in only 24% of the AF group and was a significant predictor of stroke-free survival (p = 0.04). CONCLUSIONS: New onset AF in the AMI setting carries a substantial future risk for stroke and should not be regarded as a benign, transient complication of the acute event. Long term anticoagulation is underused and is associated with improved stroke-free survival.
BACKGROUND:Atrial fibrillation (AF) in the setting of acute myocardial infarction (AMI) independently predicts in-hospital and long-term morbidity and mortality. Very little data exist regarding the prognostic significance and management of new-onset AF in this setting in the era of dual anti-platelet therapy. METHODS: We identified all patients admitted to our coronary care unit for AMI between 2002 and 2009 who developed new-onset AF. The control group was an age and gender matched group of AMI patients who did not have AF. Management and recurrent AF, non-fatal stroke, and mortality data were collected from subsequent hospitalizations and outpatient records. RESULTS: Of 1,991 AMI admissions, new-onset AF was diagnosed in 100 (4.1%). Patients' age was 70 (±12), 32% were female, 58% had ST-elevation AMI and 53% had moderate or worse systolic dysfunction. AF recurred during index admission in 33%. During mean follow-up of 41 months, AF recurred in 22 and 4.5%, and non-fatal stroke occurred in 13 and 1% of the AF and control groups, respectively (p < 0.01 for both). The composite of death and non-fatal stroke was also significantly higher in the AF group, 39 versus 29% (p = 0.02). Oral anti-coagulation was used in only 24% of the AF group and was a significant predictor of stroke-free survival (p = 0.04). CONCLUSIONS: New onset AF in the AMI setting carries a substantial future risk for stroke and should not be regarded as a benign, transient complication of the acute event. Long term anticoagulation is underused and is associated with improved stroke-free survival.
Authors: L Køber; P E Bloch Thomsen; M Møller; C Torp-Pedersen; J Carlsen; E Sandøe; K Egstrup; E Agner; J Videbaek; B Marchant; A J Camm Journal: Lancet Date: 2000-12-16 Impact factor: 79.321
Authors: Patricia Jabre; Véronique L Roger; Mohammad H Murad; Alanna M Chamberlain; Larry Prokop; Frédéric Adnet; Xavier Jouven Journal: Circulation Date: 2011-04-04 Impact factor: 29.690
Authors: Renato D Lopes; Laine E Elliott; Harvey D White; Judith S Hochman; Frans Van de Werf; Diego Ardissino; Torsten T Nielsen; W Douglas Weaver; Petr Widimsky; Paul W Armstrong; Christopher B Granger Journal: Eur Heart J Date: 2009-06-06 Impact factor: 29.983
Authors: Renato D Lopes; Aijing Starr; Carl F Pieper; Sana M Al-Khatib; L Kristin Newby; Rajendra H Mehta; Frans Van de Werf; Kenneth W Mahaffey; Paul W Armstrong; Robert A Harrington; Harvey D White; Lars Wallentin; Christopher B Granger Journal: Am J Med Date: 2010-02 Impact factor: 4.965
Authors: Christoph B Olivier; Katharina Schnabel; Christoph Brandt; Patrick Weik; Manfred Olschewski; Qian Zhou; Christoph Bode; Philipp Diehl; Martin Moser Journal: Clin Res Cardiol Date: 2014-07-16 Impact factor: 5.460